Blue Water Vaccines, Inc. (BWV) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cincinnati, OH, United States. The current CEO is Neil J. Campbell MA, MBA.
BWV has IPO date of 2022-02-18, 12 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $3.41M.
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
